ArticleCureus2021
Increased Isolation of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli From Community-Onset Urinary Tract Infection Cases in Uttarakhand, India.
Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- High Rates of Antimicrobial Resistance and Emergence of High-Risk Clones in Community-Acquired Uropathogenic Escherichia coli.MicrobiologyOpen · 2025Article
- Extended spectrum, AmpC & metallo β-lactamases producing Escherichia coli in urinary isolates: A prospective study in north India.The Indian journal of medical research · 2025Article
- Regional variations in antimicrobial susceptibility of community-acquired uropathogenicIJID regions · 2024Article
- Evaluation of Extended-Spectrum Beta-Lactamase Resistance in UropathogenicMicroorganisms · 2023Article
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
- Prevalence of Antimicrobial Resistance and Clonal Relationship in ESBL/AmpC-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.Infectious diseases and therapy · 2021Article
- Antimicrobial resistance in patients with suspected urinary tract infections in primary care in Assam, India.JAC-antimicrobial resistance · 2021Article
- Pattern of uropathogens and antibiotic sensitivity in diabetes patients attending to out - Patient department and diabetes clinic of a teaching hospital: A cross-sectional study.Journal of family medicine and primary care · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundManagement of community-acquired urinary tract infection (CA-UTI) relies heavily on empirical antibiotic therapy. Knowledge of the proportion of drug-resistant isolates especially extended-spectrum beta-lactamase (ESBL)-producing
methodOutpatient-treated CA-UTI cases were enrolled (continuously for three months), and microbiological analysis of urine sample was performed for significant bacterial growth followed by identification of conventional and matrix-assisted laser desorption/ionization-time of flight (MALDI-ToF) spectrometry method. Subsequent drug resistance and phenotypic ESBL detection were as per guidelines of the Clinical Laboratory Standard Institute (CLSI, USA). Univariate and multivariate analyses (logistic regression) of known and relevant risk factors of ESBL
conclusionHigh proportion of our community-acquired uropathogens are ESBL-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.